Brain Imaging Study

August 2, 2016 updated by: Pharmanex

A Randomized, Double-blind, Placebo-controlled Study Investigating the Effects of a Proprietary Nutritional Supplement on Brain Health

The study is designed to evaluate the effects of the proprietary nutritional supplement on cognition, mood, and brain imaging parameters following a relatively short period of treatment.

Study Overview

Study Type

Interventional

Enrollment (Actual)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Utah
      • Salt Lake City, Utah, United States, 84108
        • University of Utah - Brain Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years to 60 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Both male and female subjects will be included.
  • Age between 40-60 years inclusive.
  • Healthy subjects who, in the opinion of the investigator, are free of any medical conditions that might affect study measures.
  • Eats 1 or fewer servings of fatty fish per week.
  • BMI < 35

Exclusion Criteria:

  • Current or past neurological illness.
  • Substance abuse or dependence within the prior 60 days.
  • Current depression (HAMD greater than 20) or anxiety disorder (HAMA greater than 18).
  • Current or past history of psychiatric disorder.
  • History of head trauma with loss of consciousness.
  • Contraindication to brain MRI examination.
  • Supplementation with Omega 3, fish oil, or other over the counter supplements including the other bioactive ingredients in the proprietary nutritional supplement, antioxidants and multi-vitamin mineral supplements for the previous 3 months.
  • Plasma Omega3 Index >5% at screening visit.
  • Subject has a known allergy or intolerance to any of the ingredients contained in the proprietary nutritional supplement or placebo.
  • Subject is currently pregnant, planning to become pregnant, or is breastfeeding.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: TRIPLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
2 capsules taken by mouth with morning and evening meals.
Experimental: Proprietary Nutritional Supplement
2 capsules taken by mouth with morning and evening meals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in MRI Brain scan
Time Frame: Change from Baseline MRI Brain scan at Day 42
Determine differences in brain metabolism, brain connectivity, or brain structure. Highlight regional brain changes between pre and post chronic supplementation with a proprietary nutritional formula.
Change from Baseline MRI Brain scan at Day 42

Secondary Outcome Measures

Outcome Measure
Time Frame
Change in anxiety as measured by the Hamilton Anxiety Scale (HAM-A)
Time Frame: Change from Baseline anxiety at Day 42
Change from Baseline anxiety at Day 42
Change in depression as measured by the Hamilton Depression Rating Scale (HAM-D)
Time Frame: Change from Baseline depression at Day 42
Change from Baseline depression at Day 42
Change in mood as measured by the Profile of Mood States (POMS)
Time Frame: Change from Baseline mood at Day 42
Change from Baseline mood at Day 42
Change in memory as measured by Logical Memory I and II (subtests from the Wechsler Memory Scale- IV)
Time Frame: Change from Baseline memory at Day 42
Change from Baseline memory at Day 42
Change in fluency as measure by Letter and Category Fluency test
Time Frame: Change from Baseline fluency at Day 42
Change from Baseline fluency at Day 42
Change in Chemistry panel
Time Frame: Change from Baseline Chemistry panel at Day 42
Change from Baseline Chemistry panel at Day 42
Change in RBC fatty acid profile
Time Frame: Change from Baseline RBC fatty acid profile at Day 42
Change from Baseline RBC fatty acid profile at Day 42
Change in Gene expression
Time Frame: Change from Baseline Gene expression at Day 42
Change from Baseline Gene expression at Day 42
Measurement of polyphenol metabolites in saliva
Time Frame: Day 42
Day 42

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Deborah Yurgelun-Todd, Ph.D., University of Utah

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2015

Primary Completion (Actual)

June 1, 2016

Study Completion (Actual)

June 1, 2016

Study Registration Dates

First Submitted

April 30, 2015

First Submitted That Met QC Criteria

May 6, 2015

First Posted (Estimate)

May 12, 2015

Study Record Updates

Last Update Posted (Estimate)

August 3, 2016

Last Update Submitted That Met QC Criteria

August 2, 2016

Last Verified

August 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • 14-PHX-0002

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Health

Clinical Trials on Placebo

Subscribe